用CALGB 10403协议治疗急性淋巴细胞白血病的青少年和年轻人维持治疗中的药剂师影响的特征
Cami Andreini1,2, Brian Lam1,3, Taylor Dennison1
1Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC, USA.
概括
药剂师的干预显著改善了青少年和年轻成人急性淋巴细胞白血病 (ALL) 患者的默卡普图 (6MP) 和甲状腺素 (MTX) 的安全使用. 增加药剂师的存在导致更频繁的剂量调整和保持,提高了患者的安全性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 儿童启发的协议,如CALGB 10403,用于青少年和年轻成人 (AYA) 急性淋巴细胞白血病 (ALL).
- 课程V维护包括默卡普图 (6MP) 和口服甲状腺素 (MTX),需要密切监测和剂量调整.
研究的目的:
- 评估药剂师干预对在CALGB 10403.3课程V期间安全使用6MP和MTX的影响.
- 在AYA ALL患者中描述药剂师驱动的6MP和MTX剂量修改和中断.
主要方法:
- 在UNCMC接受CALGB 10403治疗的AYA ALL患者的回顾性图表审查 (2014年4月至2024年4月).
- 主要终点:药剂师驱动的6MP和MTX持有率.
- 二级终点:药剂师驱动的6MP和MTX剂量调整率.
主要成果:
- 所有18名患者都需要调整化疗剂量.
- 药剂师发起了71.4%的6MP和MTX剂量中断和60.7%的剂量修改.
- 添加第二个诊所药剂师增加了药剂师领导的每月保持剂量和修改率的四倍以上.
结论:
- 药剂师对于AYA ALL患者6MP和MTX的安全管理至关重要.
- 加强药剂师在诊所的存在显著改善了6MP和MTX治疗的优化.
- 这项研究强调了药剂师在优化ALL治疗期间患者安全方面的价值.
相关概念视频
01:29Therapeutic Drug Monitoring: Affecting Factors
429
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
554
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
408
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81